[클리니컬 히스토리] 에이비엘, ABL503 단독 데이터로 BD 포석

ABL바이오's clinical redesign of ABL503 represents a strategic pivot to overcome the efficacy-safety tradeoff inherent in 4-1BB monotherapies, as evidenced by prior programs like BMS's urelumab which suffered from hepatotoxicity. By combining ABL503 with PD-1 inhibitors, the company aims to validate improved anti-tumor activity while managing safety concerns—data that could significantly strengthen licensing negotiations and establish ABL503 as an independent value driver.